Pathfinder Minerals update – Balance sheet strengthened in anticipation of long awaited final resolution

May 11, 2020 | Posted by

The RNS released today by Pathfinder Minerals as per HERE sets out clearly that the Board is now looking to enter the final furlong with regards to a completion of the licence dispute that has tested the patience of shareholders for so long.

As detailed in the RNS, we have once again stepped up with our own hard earned capital to illustrate our faith in both the licence value and the impending basis of a resolution. Our recently released note – see HERE sets out our belief in the valuation parameters that could be derived from a commercially viable settlement and the basis of this valuation underpinnings.

It is evident from the RNS that it seems that not only the Veloso’s – who have in fact been on board for near 18 months now with regards to re finding a solution – but also the other 50% shareholder – the Chinese entity – have also woken up to the folly of the currently stalled basis of the licence exploitation f which there are no winners at present.

Together with the £175k of funding announced on the 3rd April the company now has approaching £500k of cash – more than adequate funding from a Plc operations perspective and plenty in the tin for associated legal costs should a settlement be concluded.

The Board reshuffle puts Dennis Edmonds squarely front of office and we have given our blessing to the option vests – with a strike of 1.25p there is a real incentive to get this done on management’s part too given the relatively de minimis salaries.

There is thus all to play for once again for all those that sail in the good ship Pathfinder Minerals!


Pathfinder is a research client of Align Research. Align Research and a director of Align Research own shares in Pathfinder and are bound to the company’s dealing policy ensuring open and adequate disclosure. Full details can be found on our website here (“Legals”).

This is a marketing communication and cannot be considered independent research. Nothing in this report should be construed as advice, an offer, or the solicitation of an offer to buy or sell securities by us. As we have no knowledge of your individual situation and circumstances the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial advisor.

Your capital is at risk by investing in securities and the income from them may fluctuate. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results. The marketability of some of the companies we cover is limited and you may have difficulty buying or selling in volume. Additionally, given the smaller capitalisation bias of our coverage, the companies we cover should be considered as high risk.

This financial promotion has been approved by Align Research Limited